CNS melanoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Section editors
SeemaNagpal.jpg
 Seema Nagpal, MD
Stanford University
Palo Alto, CA
Bethbuchbinder.jpg
 Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA
LinkedIn
5 regimens on this page
5 variants on this page

Note: these are CNS-specific regimens, please see the main melanoma page for other regimens.


Guidelines

EANO/ESMO

NCCN

All lines of therapy

Dabrafenib monotherapy

Regimen

FDA-recommended dose
Study Dates of enrollment Evidence Efficacy
Long et al. 2012 (BREAK-MB) 2011 Phase 2 (RT) ORR: 31-39%

Biomarker eligibility criteria

  • BRAF V600 mutant
  • Study Inclusion criteria: Val600Glu or Val600Lys

Targeted therapy

Continued indefinitely

References

  1. BREAK-MB: Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. Epub 2012 Oct 8. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry

Dabrafenib & Trametinib

Regimen

FDA-recommended dose
Study Dates of enrollment Evidence Efficacy
Davies et al. 2017 (COMBI-MB) 2014-2016 Phase 2 (RT) ORR: 44-59%

Biomarker eligibility criteria

  • BRAF V600 mutant
  • Clinical Trial Inclusion: BRAF V600 E/K/D/R

Targeted therapy

Continued indefinitely

References

  1. COMBI-MB: Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863-873. Epub 2017 Jun 4. link to original article contains dosing details in abstract link to PMC article PubMed Clinical Trial Registry

Fotemustine monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Mornex et al. 2003 1991-1997 Phase 3 (C) Fotemustine & WBRT Did not meet endpoint of OS
Di Giacomo et al. 2021 (NIBIT-M2) 2013-2018 Phase 3 (C) 1. Fotemustine & Ipilimumab Did not meet primary endpoint of OS
2. Ipilimumab & Nivolumab Inferior OS

Chemotherapy

References

  1. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003 Feb;13(1):97-103. link to original article PubMed
  2. NIBIT-M2: Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Cutaia O, Amato G, Covre A, Camerini R, Calabrò L, Valente M, Giannarelli D, Mandalà M, Maio M. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clin Cancer Res. 2021 Sep 1;27(17):4737-4745. Epub 2021 Jun 10. link to original article PubMed Clinical Trial Registry

Ipilimumab & Nivolumab

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Di Giacomo et al. 2021 (NIBIT-M2) 2013-2018 Phase 3 (E-esc) 1. Fotemustine Superior OS
Median OS: 29.2 vs 8.5 mo
(HR 0.44, 95% CI 0.22-0.87)
2. Fotemustine & Ipilimumab Not reported
Long et al. 2018 (ANZMTG 01.14) 2014-2017 Randomized Phase 2 (E-esc) Nivolumab Did not meet primary endpoint of intracranial response from week 12
Tawbi et al. 2018 (CheckMate 204) 2015-2017 Phase 2

Immunotherapy

  • Ipilimumab (Yervoy) as follows:
    • Cycles 1 to 4: 3 mg/kg IV once on day 1
  • Nivolumab (Opdivo) as follows:
    • Cycles 1 to 4: 1 mg/kg IV once on day 1
    • Cycle 5 onwards: 3 mg/kg IV over 60 minutes once on day 1

21-day cycle for 4 cycles, then 14-day cycles

References

  1. ANZMTG 01.14: Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
  2. CheckMate 204: Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23;379(8):722-730. link to original article link to PMC article contains dosing details in manuscript PubMed Clinical Trial Registry
    1. Update: Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 Nov 2;23(11):1961-1973. link to original article link to PMC article PubMed
  3. NIBIT-M2: Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, Guidoboni M, Marchetti P, Cutaia O, Amato G, Covre A, Camerini R, Calabrò L, Valente M, Giannarelli D, Mandalà M, Maio M. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clin Cancer Res. 2021 Sep 1;27(17):4737-4745. Epub 2021 Jun 10. link to original article PubMed Clinical Trial Registry

Vemurafenib monotherapy

Regimen

Study Dates of enrollment Evidence
McArthur et al. 2017 (MO25743) 2011-2013 Phase 2 (RT)

Biomarker eligibility criteria

Targeted therapy

References

  1. MO25743: McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017 Mar 1;28(3):634-641. link to original article PubMed Clinical Trial Registry
Retrieved from "https://hemonc.org/w/index.php?title=CNS_melanoma&oldid=71173"